These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33857885)

  • 1. Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.
    Jacobs F; Carnio S; De Stefanis P; Luciano A; Novello S
    Eur J Cancer; 2021 May; 149():114-116. PubMed ID: 33857885
    [No Abstract]   [Full Text] [Related]  

  • 2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW; Zachariae C; Simonsen AB
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.
    Basin S; Perrin J; Michot JM; Lambotte O; Cauquil C
    Eur J Cancer; 2021 Mar; 145():230-233. PubMed ID: 33517201
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.
    Bonomi M; Maltese M; Brighenti M; Muri M; Passalacqua R
    Clin Lung Cancer; 2021 Jan; 22(1):e67-e69. PubMed ID: 32952047
    [No Abstract]   [Full Text] [Related]  

  • 5. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hyponatremia from immune checkpoint inhibitor therapy for non-small cell lung cancer.
    Desikan SP; Varghese R; Kamoga R; Desikan R
    Postgrad Med J; 2020 Sep; 96(1139):570-571. PubMed ID: 31911447
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
    Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Immune Aplastic Anemia during Combined Treatment with Atezolizumab and Chemotherapy for Non-Small Cell Lung Cancer.
    Matsuki S; Taniuchi N; Okada N; Sato J; Nishijima N; Kamio K; Motoda N; Okamoto M; Seike M; Azuma A
    J Nippon Med Sch; 2024; 91(3):339-346. PubMed ID: 38972747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient.
    Chen M; Zhang L; Zhong W; Zheng K; Ye W; Wang M
    Front Immunol; 2021; 12():619147. PubMed ID: 34040602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 16. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
    Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
    J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    Passaro A; Brahmer J; Antonia S; Mok T; Peters S
    J Clin Oncol; 2022 Feb; 40(6):598-610. PubMed ID: 34985992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
    Breimer LH; Nousios P; Olsson L; Brunnström H
    Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer.
    Thompson LL; Nadelmann ER; Blum AE; Yoon J; Polyakov NJ; Kagan RD; Gainor JF; Mooradian MJ; Chen ST
    Eur J Cancer; 2021 Apr; 147():13-16. PubMed ID: 33607381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.